Trials / Withdrawn
WithdrawnNCT01295099
Keloid Scarring: Treatment and Pathophysiology
Keloid Scarring:A Randomized Clinical and Laboratory Based Study on the Treatment and Differentiation Factors of the Local Disease
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Queen Mary University of London · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
To clarify the mechanisms of Keloid scar formation. Elucidate the action and therapeutic value of 5-FU in Keloid scar treatment Identify the genetic link with Keloid scar formation. Quantify the psychological/social impact in keloid scarring patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 5- fluorouracil | 5mg of 5FU injected per 1cm square, at 6 week intervals for 30 weeks = 6 sessions |
| RADIATION | radiotherapy | after complete excision of keloid they have a single session of radiotherapy |
| DRUG | Triamcinolone | TAC 10mg in 1ml injected intralesional |
Timeline
- First posted
- 2011-02-14
- Last updated
- 2023-09-18
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01295099. Inclusion in this directory is not an endorsement.